The stock price of CRISPR Therapeutics AG (NASDAQ: CRSP) has surged by 1.69 when compared to previous closing price of 46.7, but the company has seen a 7.32% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-27 that When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock’s price, but are they really important?
Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ: CRSP) Right Now?
Moreover, the 36-month beta value for CRSP is 1.79. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 5 as “overweight,” 10 as “hold,” and 1 as “sell.”
The public float for CRSP is 82.79M and currently, short sellers hold a 25.86% of that float. On June 30, 2025, CRSP’s average trading volume was 2.34M shares.
CRSP’s Market Performance
CRSP stock saw an increase of 7.32% in the past week, with a monthly gain of 27.58% and a quarterly increase of 24.84%. The volatility ratio for the week is 4.13%, and the volatility levels for the last 30 days are 5.26% for CRISPR Therapeutics AG (CRSP). The simple moving average for the past 20 days is 12.19% for CRSP’s stock, with a 10.09% simple moving average for the past 200 days.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with Evercore ISI repeating the rating for CRSP by listing it as a “Outperform.” The predicted price for CRSP in the upcoming period, according to Evercore ISI is $99 based on the research report published on February 14, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $35. The rating they have provided for CRSP stocks is “Hold” according to the report published on February 12th, 2025.
H.C. Wainwright gave a rating of “Buy” to CRSP, setting the target price at $65 in the report published on February 03rd of the current year.
CRSP Trading at 20.64% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.42% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from Patel Naimish, who sale 3,932 shares at the price of $35.94 back on May 29 ’25. After this action, Patel Naimish now owns 6,068 shares of CRISPR Therapeutics AG, valued at $141,316 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 10,031 shares at $41.23 during a trade that took place back on Mar 21 ’25, which means that Kulkarni Samarth is holding 195,085 shares at $413,578 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -12.83 for the present operating margin
- -2.4 for the gross margin
The net margin for CRISPR Therapeutics AG stands at -10.43. The total capital return value is set at -0.23. Equity return is now at value -19.71, with -16.75 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4.
Currently, EBITDA for the company is -447.31 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 110.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.64.
Conclusion
To wrap up, the performance of CRISPR Therapeutics AG (CRSP) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
